Vivoryon is a clinical stage biotechnology company focused on developing innovative small molecule-based medicines for the treatment of inflammatory and fibrotic disorders of the kidney. Driven by its passion for ground-breaking science and innovation, the Company strives to improve patient outcomes by changing the course of severe diseases through modulating the activity and stability of pathologically relevant proteins. Vivoryon’s most advanced program, varoglutamstat, a proprietary, first-in-class orally available QPCT/L inhibitor, is being evaluated to treat diabetic kidney disease.
Company Details
- Employees
- 20
- Founded
- -
- Address
- Weinbergweg 22, Halle (Saale),06120,germany
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- probiodrug.de
- Keywords
- AG.
- HQ
- Halle (Saale)
Vivoryon Therapeutics N.v. Questions
Vivoryon Therapeutics N.V.'s website is probiodrug.de
Vivoryon Therapeutics N.V.'s LinkedIn profile is https://de.linkedin.com/company/vivoryon
Vivoryon Therapeutics N.V. has
20 employees.
View email and phone details for 20
employees at Vivoryon Therapeutics N.V..
Vivoryon Therapeutics N.V.'s industry is
Biotechnology Research
Vivoryon Therapeutics N.V.'s top competitors are
Thermosome,
Inflarx,
Noselab,
Atai Life Sciences,
Viopas Venture Consulting Gmbh,
Immatics,
Atriva Therapeutics Gmbh,
Medigene Ag,
Affimed,
Seamless Therapeutics.
Vivoryon Therapeutics N.V.'s categories are Biotechnology Research
Vivoryon Therapeutics N.V.'s founding year is 1997
